Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study investigates the feasibility of the Labcorp Plasma Detect, which is an assay (test) that looks for circulating tumor DNA (ctDNA) in patients who have muscle-invasive (MI) urothelial carcinoma (also known as MI bladder cancer, MIBC). During this study, tissue, blood and urine samples will also be analyzed to help the study team better understand this type of cancer and a patient's response to treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Nowo rozpoznany rak pęcherza moczowego potwierdzony badaniem mikroskopowym
- •Kwalifikacja do leczenia chirurgicznego, radioterapii lub chemioterapii z zamiarem wyleczenia
- •Posiadanie próbki guza z diagnostyki do analizy
- •Możliwość zrozumienia i podpisania zgody na uczestnictwo w badaniu
✗ Disqualifies
- •Jednoczesne leczenie innego rodzaju nowotworu
- •Historia innego nowotworu (poza rakiem pęcherza)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
OHSU Knight Cancer Institute
Portland, United States
Trial contact
Jen-Jane Liu
Jen-Jane Liu
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.